BACKGROUND AND PURPOSE: Decreased diffusion (DD) consistent with acute ischemia may be detected on MRI after acute intracerebral hemorrhage (ICH), but its risk factors and impact on functional outcomes are not well-defined. We tested the hypotheses that DD after ICH is related to acute blood pressure (BP) reduction and lower hemoglobin and presages worse functional outcomes. METHODS: Patients who underwent MRI were prospectively evaluated for DD by certified neuroradiologists blinded to outcomes. Hemoglobin and BP data were obtained via electronic queries. Outcomes were obtained at 14 days and 3 months with the modified Rankin Scale, a functional scale scored from 0 (no symptoms) to 6 (dead). We used logistic regression for dependence or death (modified Rankin Scale score 4-6). RESULTS: DD distinct from the hematoma was found on MRI in 39 of 95 patients (41%). DD was associated with greater BP reductions from baseline and a higher risk of dependence or death at 3 months (odds ratio, 4.8; 95% confidence interval, 1.7-13.9; P=0.004) after correction for ICH score (1.8 per point; 95% confidence interval, 1.2-3.1; P=0.01). Lower hemoglobin was associated with worse ICH score, larger hematoma volume, and worse outcomes, but not DD. CONCLUSIONS: DD is common after ICH, associated with greater acute BP reductions, and associated with disability and death at 3 months in multivariate analysis. The potential benefits of acute BP reduction to reduce hematoma growth may be limited by DD. The prevention and treatment of cerebral ischemia manifested as DD are potential methods to improve outcomes.
BACKGROUND AND PURPOSE: Decreased diffusion (DD) consistent with acute ischemia may be detected on MRI after acute intracerebral hemorrhage (ICH), but its risk factors and impact on functional outcomes are not well-defined. We tested the hypotheses that DD after ICH is related to acute blood pressure (BP) reduction and lower hemoglobin and presages worse functional outcomes. METHODS:Patients who underwent MRI were prospectively evaluated for DD by certified neuroradiologists blinded to outcomes. Hemoglobin and BP data were obtained via electronic queries. Outcomes were obtained at 14 days and 3 months with the modified Rankin Scale, a functional scale scored from 0 (no symptoms) to 6 (dead). We used logistic regression for dependence or death (modified Rankin Scale score 4-6). RESULTS:DD distinct from the hematoma was found on MRI in 39 of 95 patients (41%). DD was associated with greater BP reductions from baseline and a higher risk of dependence or death at 3 months (odds ratio, 4.8; 95% confidence interval, 1.7-13.9; P=0.004) after correction for ICH score (1.8 per point; 95% confidence interval, 1.2-3.1; P=0.01). Lower hemoglobin was associated with worse ICH score, larger hematoma volume, and worse outcomes, but not DD. CONCLUSIONS:DD is common after ICH, associated with greater acute BP reductions, and associated with disability and death at 3 months in multivariate analysis. The potential benefits of acute BP reduction to reduce hematoma growth may be limited by DD. The prevention and treatment of cerebral ischemia manifested as DD are potential methods to improve outcomes.
Authors: J T Lindsay Wilson; Asha Hareendran; Marie Grant; Tracey Baird; Ursula G R Schulz; Keith W Muir; Ian Bone Journal: Stroke Date: 2002-09 Impact factor: 7.914
Authors: T Brott; H P Adams; C P Olinger; J R Marler; W G Barsan; J Biller; J Spilker; R Holleran; R Eberle; V Hertzberg Journal: Stroke Date: 1989-07 Impact factor: 7.914
Authors: J Fiebach; O Jansen; P Schellinger; M Knauth; M Hartmann; S Heiland; H Ryssel; O Pohlers; W Hacke; K Sartor Journal: Neuroradiology Date: 2001-08 Impact factor: 2.804
Authors: P M Vespa; K O'Phelan; M Shah; J Mirabelli; S Starkman; C Kidwell; J Saver; M R Nuwer; J G Frazee; D A McArthur; N A Martin Journal: Neurology Date: 2003-05-13 Impact factor: 9.910
Authors: Dorothee Saur; Thomas Kucinski; Ulrich Grzyska; Bernd Eckert; Christian Eggers; Wolf Niesen; Volker Schoder; Hermann Zeumer; Cornelius Weiller; Joachim Röther Journal: AJNR Am J Neuroradiol Date: 2003-05 Impact factor: 3.825
Authors: J B Fiebach; P D Schellinger; O Jansen; M Meyer; P Wilde; J Bender; P Schramm; E Jüttler; J Oehler; M Hartmann; S Hähnel; M Knauth; W Hacke; K Sartor Journal: Stroke Date: 2002-09 Impact factor: 7.914
Authors: Eitan Auriel; M Brandon Westover; Matt T Bianchi; Yael Reijmer; Sergi Martinez-Ramirez; Jun Ni; Ellis Van Etten; Matthew P Frosch; Panagiotis Fotiadis; Kris Schwab; Anastasia Vashkevich; Grégoire Boulouis; Alayna P Younger; Keith A Johnson; Reisa A Sperling; Trey Hedden; M Edip Gurol; Anand Viswanathan; Steven M Greenberg Journal: Stroke Date: 2015-07-09 Impact factor: 7.914
Authors: Santosh B Murthy; Ivan Diaz; Xian Wu; Alexander E Merkler; Costantino Iadecola; Monika M Safford; Kevin N Sheth; Babak B Navi; Hooman Kamel Journal: Stroke Date: 2019-11-27 Impact factor: 7.914
Authors: Rajeev K Garg; Jawad Khan; Robert J Dawe; James Conners; Sayona John; Shyam Prabhakaran; Mehmet Kocak; Sudeep Bhabad; Sean L Simpson; Bichun Ouyang; Miral Jhaveri; Thomas P Bleck Journal: Neurocrit Care Date: 2020-10 Impact factor: 3.210
Authors: Shannon Hextrum; Jatinder S Minhas; Eric M Liotta; Farzaneh A Sorond; Andrew M Naidech; Matthew B Maas Journal: J Neurol Sci Date: 2020-09-12 Impact factor: 3.181
Authors: Andrew M Naidech; Jennifer L Beaumont; Neil F Rosenberg; Matthew B Maas; Adam R Kosteva; Michael L Ault; David Cella; E Wesley Ely Journal: Am J Respir Crit Care Med Date: 2013-12-01 Impact factor: 21.405
Authors: Matthew B Maas; Neil F Rosenberg; Adam R Kosteva; Rebecca M Bauer; James C Guth; Eric M Liotta; Shyam Prabhakaran; Andrew M Naidech Journal: Neurology Date: 2013-06-05 Impact factor: 9.910
Authors: Lucia Rivera-Lara; Santosh B Murthy; Saman Nekoovaght-Tak; Hasan Ali; Nichol McBee; Rachel Dlugash; Malathi Ram; Richard Thompson; Issam A Awad; Daniel F Hanley; Wendy C Ziai Journal: Neurocrit Care Date: 2018-10 Impact factor: 3.210